Provectus Biopharmaceuticals, Inc. (PVCT)
OTCMKTS · Delayed Price · Currency is USD
0.0618
+0.0008 (1.31%)
May 6, 2026, 1:05 PM EST
PVCT Revenue
In the year 2025, Provectus Biopharmaceuticals had annual revenue of $336.11K, down -45.54%.
Revenue
336.11K
Revenue Growth
-45.54%
P/S Ratio
76.78
Revenue / Employee
56.02K
Employees
6
Market Cap
25.81M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 336.11K | -281.03K | -45.54% |
| Dec 31, 2024 | 617.14K | 59.43K | 10.66% |
| Dec 31, 2023 | 557.71K | -431.33K | -43.61% |
| Dec 31, 2022 | 989.04K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| HOOKIPA Pharma | 9.35M |
| Zeo ScientifiX | 5.56M |
| Harvard Apparatus Regenerative Technology | 704.00K |
| ZIVO Bioscience | 209.03K |
| Arch Biopartners | 115.29K |
Provectus Biopharmaceuticals News
- 2 days ago - Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus's VisiRose Subsidiary and Rose Bengal Sodium in Infectious Keratitis - GlobeNewsWire
- 15 days ago - Provectus Biopharmaceuticals to Hold 2026 Annual Meeting of Stockholders at Perkins Place, Its Planned New Headquarters in Knoxville, Tennessee - GlobeNewsWire
- 4 weeks ago - Provectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; Porcine Study Demonstrates Shift Toward Pro-Regenerative Tissue Environment - GlobeNewsWire
- 7 months ago - Provectus Biopharmaceuticals Positions PV-10 as a Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel STING-Pathway Activation for Improving Hepatitis B Vaccine Efficacy - GlobeNewsWire
- 7 months ago - Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder Cancer - GlobeNewsWire
- 11 months ago - Provectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck Cancer - GlobeNewsWire
- 11 months ago - Provectus Biopharmaceuticals Announces Investor Webinar for 2025 Annual Meeting of Stockholders - GlobeNewsWire
- 1 year ago - Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus's Spinoff Company for Rose Bengal-Based Eye Drugs - GlobeNewsWire